Incyte And Mirati Therapeutics Enter To Evaluate INCB99280 And Adagrasib In Patients With KRASG12C-Mutated Solid Tumors
“While monoclonal antibodies targeting PD‑L1 or PD-1 have transformed the treatment landscape in oncology, they are limited by their route of administration and long-half life and receptor occupancy which can affect the management of immune-related adverse events,” said Lance Leopold, M.D., Group Vice President, Clinical Development Hematology and Oncology, Incyte. “Incyte’s small molecule, oral PD-L1 program has shown promising safety and efficacy in early studies – INCB99280’s shorter half life may result in improved management of immune mediated adverse events and better clinical outcomes. We are pleased to collaborate with Mirati to conduct the first clinical trial of INCB99280 plus adagrasib, two orally-bioavailable molecules, in patients with KRASG12C-mutated solid tumors.”
Share:
More News
Dr. Michael Ge, CEO of Kelun-Biotech said, “We are delighted to see the acceptance of the fifth indication application for sac-TMT. Compared to immunotherapy alone, the ADC combination with KEYTRUDA® as first-line treatment for PD-L1-positive NSCLC has achieved not only positive results in PFS, but also a trend toward benefit
“We are excited to work with Merck to advance this promising investigational combination in RAS-driven cancers,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “RAS mutations activate the RAS/MAPK pathway and promote an immunosuppressive environment. Non-clinical data suggest that targeting the pathway with ERAS-0015 may complement PD-1 blockade
“Dosing the first patient in the ASPENOVA Phase 3 clinical trial represents a significant milestone in our development of azenosertib for patients with platinum-resistant ovarian cancer,” said Ingmar Bruns, M.D., Chief Medical Officer of Zentalis. “With DENALI Part 2 progressing toward a year-end readout that may support accelerated approval and
“The depth, durability, and consistency of responses observed across both the total population and BTKi-treated subsets underscore iopofosine’s potential as a meaningful new treatment option in WM and differentiate it from currently available therapies,” said Jarrod Longcor, chief operating officer of Cellectar Biosciences. “With the completion of at least 12-month